What question did this study set out to answer?

The central aim is to develop a framework to predict clinical responses to an anti-April monoclonal antibody for IgAN.

March 28, 2026Open Access

WCN26-5830 A TRANSLATIONAL FRAMEWORK TO PREDICT CLINICAL RESPONSES TO APRIL BLOCKADE FOR DEVELOPMENT OF JADE101, AN ANTI-APRIL MONOCLONAL ANTIBODY IN IgAN

Key Points

The central aim is to develop a framework to predict clinical responses to an anti-April monoclonal antibody for IgAN.
Translational framework development based on protein trafficking and folding analysis.
Assessment of allele-dependent effectiveness of PBA.
Evaluation of personalized treatment strategies for patients with hypomorphic mutations.
Promising evidence indicates personalized treatment can benefit patients with specific mutations.
Further clinical investigations are warranted to validate preclinical findings.

Abstract

improving protein folding and trafficking of pathogenic PC1 variants.The allele-dependent effectiveness of PBA indicates its potential as a personalized treatment strategy, specifically benefiting patients with hypomorphic mutations.Further clinical investigations are warranted to validate these promising preclinical outcomes.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.

Bookmark

View Full Paper

Bookmark

View Full Paper

WCN26-5830 A TRANSLATIONAL FRAMEWORK TO PREDICT CLINICAL RESPONSES TO APRIL BLOCKADE FOR DEVELOPMENT OF JADE101, AN ANTI-APRIL MONOCLONAL ANTIBODY IN IgAN

Key Points

Abstract

Cite This Study